Stemtech Secures Inventory Funding

According to a recent press release:

Stemtech secures funding for production of $2.5 Million of Inventory to protect against potential supply chain interruptions.

NAPLES, FL – Stemtech Corporation (OTC: STEK), the global leader and pioneer in stem cell nutrition, announces that they have successfully secured funding to acquire raw materials and components for production of $2.5 million of inventory. This strategic investment, already in hand with purchase orders issued for the first million, is essential for maintaining a steady and sufficient stock of our premium-stem cell nutrition and regenerative science products, which have been integral to our company’s mission for over twenty years, according to company leadership.

Charles S. Arnold, Stemtech’s Chairman and CEO, stated:

“We have received substantial funding to expand inventory production. Our 20 years of experience affirm the vital role our products play in natural human supplementation, particularly in areas related to anti-aging and longevity. These products have proven themselves essential tools for individuals seeking to enhance their health naturally while providing anti-aging effectively.

“As a company, Stemtech is deeply committed to health and wellness, and we recognize the critical importance of product availability. Over the past year, increased demand for our key core products has occasionally resulted in out-of-stock situations. These interruptions of product availability have been disappointing, not only for our customers but also for our dedicated Stemtech company team, who understand the benefits our products provide in supporting the body’s natural regenerative processes.”

President and COO, John W. Meyer, added:

“We want to emphasize the significance of this investment. Having sufficient inventory on hand means that Stemtech can now provide an uninterrupted supply to meet the fast-growing demand for not only our network marketing business (stemtech.com) to support our Independent Business Partners (IBPs), but also our growing retail operations.

“This development enables our customers and partners to have greater confidence in consistently accessing the products they trust and rely upon. We take great pride in our ability to support the health and wellness journeys of so many people worldwide.”

Alejandro Carrillo, Vice President of Global Operations, emphasized the operational advantages this funding provides:

“With a strong inventory foundation, we are better positioned to successfully expand our reach through retail channels and online platforms, including our recently launched StemtechBiosciences.com e-commerce offering. Ensuring product availability across all our markets and beyond is vital as we continue our planned expansion efforts.”

Stemtech recognizes the importance of strategic investments to safeguard the company’s ability to deliver excellence while advancing as the pioneer and leader in regenerative science and nutrition.

About Stemtech

Stemtech Corporation (OTC: STEK) is a publicly traded wellness company specializing in stemceuticals^™ – all-natural, plant-based nutritional solutions designed to support the body’s natural regenerative processes. Founded in 2018, following the acquisition of the operations from Stemtech International, Inc., (established in 2005), the company has a long history of innovation in stem cell nutrition and wellness science. For over 20 years, Stemtech has not only championed the benefits of natural, plant-based ingredients but has also led the way in scientific innovation within the wellness, anti-aging and longevity sectors with its unwavering commitment to quality and innovation.